Archived News

ConforMIS has expanded its Series E financing to $167.7 million with participation from top-tier Sovereign Wealth Funds, Government Investment Funds and Private Equity Funds in the U.S., Europe, Asia and the Middle East. ConforMIS will use the funds to expand its commercialization of the iTotal® G2 total knee replacement system in the U.S. and abroad, advance its manufacturing capabilities and invest in new market opportunities.

ConforMIS has appointed orthopedic industry veteran Matthew Scott as the company’s Senior Vice President of Operations. Mr. Scott brings extensive operations experience to ConforMIS, including over a decade of medical device manufacturing and operations leadership with Zimmer Orthopedics and Zimmer Dental.

Dr. Philipp Lang, CEO of ConforMIS, will provide an overview of the company beginning at 8:00 am PST (11:00 am EST). ConforMIS is the leading provider of patient-specific knee replacement implants and instruments, and currently the fastest growing company in orthopedics.

ConforMIS has appointed 30-year business and financial management veteran Peter Traynor as the company’s Chief Financial Officer. The addition of Mr. Traynor bolsters the executive management team as the company continues to grow following the recent launch of its iTotal®G2 total knee replacement system.

ConforMIS has relocated its headquarters to 28 Crosby Drive in Bedford, MA. The new space, combined with the manufacturing facility in Burlington, quadruples the total square footage of the company’s existing property. The company now has more than 120,000 square feet available for its operations.

ConforMIS announced the commercial availability of its iTotal® G2 Knee Replacement System, the only patient-specific total knee replacement (TKR) available on the market today. The iTotal G2 is the next generation version of the iTotal which was FDA cleared in January 2011 and launched into limited surgeon release in May 2011.

ConforMIS’ iTotal® CR Knee Replacement System has been awarded Silver in the “Implant and Tissue-Replacement Products” category of the 2012 Medical Design Excellence Awards (MDEA) competition. The MDEA is the industry’s premier competition recognizing significant advances in medical product design and engineering that improve the quality of healthcare delivery and accessibility.

ConforMIS announced it has completed its most productive period to date in the development of its intellectual property with the addition of 22 issued patents to its portfolio since January 2011. The core of its portfolio covers patient-specific implants and patient-specific instrumentation systems spanning applications in knee, hip, shoulder, small joint, and spine. With these recent patent awards, ConforMIS now owns or exclusively licenses more than 50 issued patents.